BUZZ-Oncolytics Biotech Inc: Orphan status for pancreatic cancer drug
** Canadian drug developer's shares up 25.4 pct at 65 cents premarket
** FDA grants orphan drug designation for company's pancreatic cancer drug candidate
** Drug already received status for ovarian cancer
** Orphan drug status granted to drugs developed to treat rare diseases; gives drug developer incentives, including 7-year marketing exclusivity
** Up to Friday's close, stock had fallen more than 68 percent in past 12 months
© Thomson Reuters 2017 All rights reserved.